Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00632359 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00632359: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00632359 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00632359, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if Revlimid (lenalidomide) can help to reduce the level of leukemia in your body. The safety of this drug will also be studied.
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-02 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00632359
The ClinicalTrials.gov registry entry for NCT00632359 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT00632359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00632359 about?
NCT00632359 is a clinical study titled "Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease". The goal of this clinical research study is to learn if Revlimid (lenalidomide) can help to reduce the level of leukemia in your body. The safety of this drug will also be studied.
What is the current status of trial NCT00632359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2008-02. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00632359?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00632359?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.